Literature DB >> 11849314

Influence of CD4 T cells and the source of major histocompatibility complex class II-restricted peptides on cytotoxic T-cell priming by dendritic cells.

Brenda Faiola1, Carolyn Doyle, Eli Gilboa, Smita Nair.   

Abstract

We have previously reported that bone marrow derived dendritic cells (DC) pulsed with major histocompatibility complex (MHC) class I-restricted peptide efficiently prime a cytotoxic T lymphocyte (CTL) response in vivo. Here we assess the involvement of CD4(+) T cells in the induction of CD8(+) CTL by DC by testing the ability of class II-deficient (C2D) DC, class II mutant (Alpha beta mut) DC and autologous serum generated DC (AS DC) to present class I-restricted antigens in vitro and in vivo. DC generated from the bone marrow of class II knockout mice and transgenic mice expressing a mutant class II that can not bind CD4 were phenotypically similar to wild type (wt) DC, except with regard to MHC class II expression. The C2D and Alpha beta mut DC, though fully capable of presenting the class I-restricted ovalbumin (OVA) peptide to a T-cell hybridoma in vitro, failed to prime a CTL response in vivo. Restoration of class II expression on C2D DC allowed priming of a CTL response; thus, the defect in CTL priming was indeed caused by the absence of class II expression. Likewise, DC generated in autologous serum were unable to prime a CTL response as these DC only express 'self' class II epitopes and therefore would not activate syngeneic CD4(+) T cells. Addition of exogenous class II epitopes rescued the ability of AS DC to prime a CTL response. These observations provide convincing evidence that efficient CTL induction by DC in vivo requires concomitant presentation of class II epitopes for CD4(+) T-cell induction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11849314      PMCID: PMC1782635          DOI: 10.1046/j.0019-2805.2001.01343.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  30 in total

1.  Retrovirally transduced mouse dendritic cells require CD4+ T cell help to elicit antitumor immunity: implications for the clinical use of dendritic cells.

Authors:  S Schnell; J W Young; A N Houghton; M Sadelain
Journal:  J Immunol       Date:  2000-02-01       Impact factor: 5.422

2.  The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. III. Eradication of disseminated murine chronic leukemia cells by utilizing MDP hapten-reactive helper T-cell activity.

Authors:  J Shima; T Yoshioka; H Nakajima; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

3.  Introduction of soluble protein into the class I pathway of antigen processing and presentation.

Authors:  M W Moore; F R Carbone; M J Bevan
Journal:  Cell       Date:  1988-09-09       Impact factor: 41.582

4.  T4+ T helper cell function in vivo: differential requirement for induction of antiviral cytotoxic T-cell and antibody responses.

Authors:  R Ahmed; L D Butler; L Bhatti
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

5.  Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response.

Authors:  E R Fearon; D M Pardoll; T Itaya; P Golumbek; H I Levitsky; J W Simons; H Karasuyama; B Vogelstein; P Frost
Journal:  Cell       Date:  1990-02-09       Impact factor: 41.582

6.  The generation and activation of memory class I MHC restricted cytotoxic T cell responses to influenza A virus in vivo do not require CD4+ T cells.

Authors:  Y Liu; A Müllbacher
Journal:  Immunol Cell Biol       Date:  1989-12       Impact factor: 5.126

7.  Induction of cytotoxic T-cell responses in vivo in the absence of CD4 helper cells.

Authors:  R M Buller; K L Holmes; A Hügin; T N Frederickson; H C Morse
Journal:  Nature       Date:  1987 Jul 2-8       Impact factor: 49.962

8.  The lymphoreticular system in triggering virus plus self-specific cytotoxic T cells: evidence for T help.

Authors:  R M Zinkernagel; G N Callahan; A Althage; S Cooper; J W Streilein; J Klein
Journal:  J Exp Med       Date:  1978-03-01       Impact factor: 14.307

9.  Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism.

Authors:  H G Ljunggren; K Kärre
Journal:  J Exp Med       Date:  1985-12-01       Impact factor: 14.307

10.  Helper activity is required for the in vivo generation of cytotoxic T lymphocytes.

Authors:  J A Keene; J Forman
Journal:  J Exp Med       Date:  1982-03-01       Impact factor: 14.307

View more
  2 in total

Review 1.  The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors.

Authors:  Peter E Fecci; Duane A Mitchell; Gary E Archer; Michael A Morse; H Kim Lyerly; Darell D Bigner; John H Sampson
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

Review 2.  Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets.

Authors:  Florian Wimmers; Gerty Schreibelt; Annette E Sköld; Carl G Figdor; I Jolanda M De Vries
Journal:  Front Immunol       Date:  2014-04-11       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.